Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.
Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.
On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.
The Vanguard Group amended a Schedule 13G/A to report 0% beneficial ownership of Protagonist Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries now report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PTGX Form 144 shows recent proposed and completed sales of Common Stock. The excerpt lists a planned stock option exercise to sell 24,765 shares for cash on 03/26/2026. It also records two completed sales by Asif Ali: 46,203 shares on 01/27/2026 for $3,841,128.28 and 8,588 shares on 01/20/2026 for $708,327.08. Shares outstanding are listed as 63,808,716 as of 03/26/2026.
PTGX submitted a Form 144 reporting the sale of 15,000 shares via a stock option exercise to be settled for cash on 03/26/2026. The filing lists prior open-market dispositions by Arturo Molina, including 5,000 shares on 01/27/2026 and 13,151 shares on 01/23/2026.
Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock. On March 24–25, he exercised stock options covering 54,700 shares of Common Stock at an exercise price of $8.58 per share and acquired the same number of shares.
He then sold 54,700 Common Stock shares in open-market transactions at $101.00 per share. On March 23, he made a bona fide gift of 50,000 Common Stock shares to relatives. Following these transactions, Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock.
PTGX submitted a Form 144 reporting a proposed sale of 54,700 shares of Common Stock via an option exercise on 03/24/2026, with proceeds to be received in cash. The filing also lists prior open-market dispositions by Dinesh Patel of 19,315 shares on 01/23/2026, 24,890 shares on 01/26/2026, and 4,068 shares on 01/27/2026.
Protagonist Therapeutics outlines a broad late‑ and early‑stage pipeline built on its peptide platform across inflammation, hematology and obesity. Lead asset Icotyde, an oral IL‑23 receptor antagonist licensed to Janssen, has marketing applications filed with the FDA and EMA for moderate‑to‑severe plaque psoriasis, with Janssen guiding to a potential 2026 U.S. launch, subject to approval.
Rusfertide, an injectable hepcidin mimetic for polycythemia vera partnered with Takeda, has an NDA filed in the United States and has Fast Track, Orphan Drug and Breakthrough Therapy designations. Protagonist and Takeda currently share U.S. profits and losses 50/50, and Protagonist expects to exercise a contractual opt‑out in 2026 that would convert this into a global royalty stream.
The company is also advancing PN‑881, an oral IL‑17 antagonist now in Phase 1, an oral hepcidin mimetic PN‑8047, and two obesity candidates, PN‑477 (triple GLP‑1/GIP/glucagon agonist) and PN‑458 (dual GLP‑1/GIP agonist), both with planned oral and injectable formulations. Protagonist ended 2025 with approximately $646.0 million in cash, cash equivalents and marketable securities, up from $559.2 million at year‑end 2024, and remains eligible for substantial future milestones and royalties from its Janssen and Takeda collaborations.